Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study

Licia Grazzi, Gabriella Egeo, Eric Liebler, Anna Maria Padovan, Piero Barbanti

Research output: Contribution to journalArticle

Abstract

Recent clinical experiences and clinical trials have demonstrated the safety, tolerability, and efficacy of non-invasive vagus nerve stimulation (nVNS; gammaCore®) for the acute and prophylactic treatment of migraine. nVNS has a favorable adverse event profile, making it an attractive option for sensitive patient populations. We explored the safety, tolerability, and efficacy of nVNS as acute migraine treatment in adolescents. A group of adolescent patients suffering from migraine without aura were trained to use gammaCore to manage their migraine attacks. 46.8% of the treated migraine attacks (22/47) were considered successfully treated and did not require any rescue medication. No device-related adverse events were recorded. This preliminary study suggests that nVNS may represent a safe, well-tolerated, and effective for acute migraine treatment in adolescents.

Original languageEnglish
Pages (from-to)197-199
Number of pages3
JournalNeurological Sciences
Volume38
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Vagus Nerve Stimulation
Migraine Disorders
Safety
Migraine without Aura
Therapeutics
Vulnerable Populations
Clinical Trials
Equipment and Supplies

Keywords

  • gammaCore device
  • Migraine without aura
  • nVNS approach
  • Symptomatic treatment
  • Young age

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients : a preliminary safety study. / Grazzi, Licia; Egeo, Gabriella; Liebler, Eric; Padovan, Anna Maria; Barbanti, Piero.

In: Neurological Sciences, Vol. 38, 01.05.2017, p. 197-199.

Research output: Contribution to journalArticle

@article{c4669a0271c54961bc2ba959750f5d5b,
title = "Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study",
abstract = "Recent clinical experiences and clinical trials have demonstrated the safety, tolerability, and efficacy of non-invasive vagus nerve stimulation (nVNS; gammaCore{\circledR}) for the acute and prophylactic treatment of migraine. nVNS has a favorable adverse event profile, making it an attractive option for sensitive patient populations. We explored the safety, tolerability, and efficacy of nVNS as acute migraine treatment in adolescents. A group of adolescent patients suffering from migraine without aura were trained to use gammaCore to manage their migraine attacks. 46.8{\%} of the treated migraine attacks (22/47) were considered successfully treated and did not require any rescue medication. No device-related adverse events were recorded. This preliminary study suggests that nVNS may represent a safe, well-tolerated, and effective for acute migraine treatment in adolescents.",
keywords = "gammaCore device, Migraine without aura, nVNS approach, Symptomatic treatment, Young age",
author = "Licia Grazzi and Gabriella Egeo and Eric Liebler and Padovan, {Anna Maria} and Piero Barbanti",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10072-017-2942-5",
language = "English",
volume = "38",
pages = "197--199",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients

T2 - a preliminary safety study

AU - Grazzi, Licia

AU - Egeo, Gabriella

AU - Liebler, Eric

AU - Padovan, Anna Maria

AU - Barbanti, Piero

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Recent clinical experiences and clinical trials have demonstrated the safety, tolerability, and efficacy of non-invasive vagus nerve stimulation (nVNS; gammaCore®) for the acute and prophylactic treatment of migraine. nVNS has a favorable adverse event profile, making it an attractive option for sensitive patient populations. We explored the safety, tolerability, and efficacy of nVNS as acute migraine treatment in adolescents. A group of adolescent patients suffering from migraine without aura were trained to use gammaCore to manage their migraine attacks. 46.8% of the treated migraine attacks (22/47) were considered successfully treated and did not require any rescue medication. No device-related adverse events were recorded. This preliminary study suggests that nVNS may represent a safe, well-tolerated, and effective for acute migraine treatment in adolescents.

AB - Recent clinical experiences and clinical trials have demonstrated the safety, tolerability, and efficacy of non-invasive vagus nerve stimulation (nVNS; gammaCore®) for the acute and prophylactic treatment of migraine. nVNS has a favorable adverse event profile, making it an attractive option for sensitive patient populations. We explored the safety, tolerability, and efficacy of nVNS as acute migraine treatment in adolescents. A group of adolescent patients suffering from migraine without aura were trained to use gammaCore to manage their migraine attacks. 46.8% of the treated migraine attacks (22/47) were considered successfully treated and did not require any rescue medication. No device-related adverse events were recorded. This preliminary study suggests that nVNS may represent a safe, well-tolerated, and effective for acute migraine treatment in adolescents.

KW - gammaCore device

KW - Migraine without aura

KW - nVNS approach

KW - Symptomatic treatment

KW - Young age

UR - http://www.scopus.com/inward/record.url?scp=85019589134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019589134&partnerID=8YFLogxK

U2 - 10.1007/s10072-017-2942-5

DO - 10.1007/s10072-017-2942-5

M3 - Article

AN - SCOPUS:85019589134

VL - 38

SP - 197

EP - 199

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -